Eli Lilly Acquires SiteOne Therapeutics in $1B Deal to Bolster Non-Opioid Pain

Indianapolis, IN, May 27, 2025 (PRNewswire) -- Eli Lilly and Company announced it will acquire SiteOne Therapeutics, a biotech firm focused on non-opioid pain treatments, in a deal worth up to $1 billion. The acquisition centers around STC-004, a Phase 2-ready sodium channel inhibitor targeting chronic pain. This move underscores Lilly's commitment to developing innovative, addiction-free pain management solutions.

Read full article here.